Latest Generic Drugs News

AstraZeneca Q2 profits up 22 pct
AstraZeneca PLC doubled its share buyback program on Thursday after posting strong second quarter results and revealing that a key new drug — its blood thinner Brilinta — has been given a thumbs up by an advisory committee of the U.S. Food and Drug Administration.
Read more on AP via Yahoo! News